Document is current
Any future updates will be listed below
-
Authors
Kassel, Sara https://orcid.org/0000-0002-6612-4167
Yuan, Kai
Bunnag, Nawat
Neitzel, Leif R. https://orcid.org/0000-0003-2621-6259
Lu, Wenhui
Schwarzkopf, Anna
Maines, Benjamin https://orcid.org/0000-0002-0374-2726
Loberg, Matthew A. https://orcid.org/0000-0001-5840-4591
Xu, George
Adams, Amber
McCray, Andrew D.
Cho, Alex
Rockouski, Mary
Orton, Gemma
Goldsmith, Lily
Aronno, Md Mubtaseem Ahnaf
Spencer, Zachary T.
Khan, Omar M. https://orcid.org/0000-0001-7062-4677
Ye, Fei https://orcid.org/0000-0001-6472-5076
Williams, Charles https://orcid.org/0000-0002-0331-5652
Lebensohn, Andres M. https://orcid.org/0000-0002-4224-8819
Rohatgi, Rajat https://orcid.org/0000-0001-7609-8858
Wang, Xiaofeng https://orcid.org/0000-0001-7611-4491
Weiss, Vivian L. https://orcid.org/0000-0003-0874-3207
Hong, Charles C.
Kettenbach, Arminja N. https://orcid.org/0000-0003-3979-4576
Robbins, David J. https://orcid.org/0000-0003-0190-2973
Ahmed, Yashi https://orcid.org/0000-0002-7472-6010
Lee, Ethan https://orcid.org/0000-0001-8405-6156
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Center for Scientific Review (R01CA244188)
- License Information
-
More Information
Article History
Received: 21 December 2023
Accepted: 27 May 2025
First Online: 5 June 2025
Competing interests
: E.L. and D.J.R. are co-founders of StemSynergy Therapeutics, a company that seeks to develop inhibitors of major signaling pathways (including the Wnt pathway) for the treatment of cancer. The remaining authors declare that they have no competing interests.
